This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 7, 2003 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
Compounding for the Effects of Weapons of Mass Destruction |
Vol. 7 No. 1 |
10 |
Diabetes Mellitus: Pathophysiology and Complications |
Vol. 7 No. 1 |
17 |
Profile of a Practice: Ward Drug Company Diabetic Shoppe and Prescription Compounding Center |
Vol. 7 No. 1 |
21 |
Natural or Bioidentical Hormone Replacement: What makes the Difference? An Interview with Christopher B. Cutter, MD. |
Vol. 7 No. 1 |
24 |
Equine Cushing’s Syndrome |
Vol. 7 No. 1 |
27 |
Establishing and Standardizing Preferred Pharmacy Practices in a Multioffice Infusion Company, Part 2 |
Vol. 7 No. 1 |
32 |
Packaging Choices for Compounded Materials |
Vol. 7 No. 1 |
37 |
Technology Spotlight: Barrier Isolators |
Vol. 7 No. 1 |
42 |
Determining the Availability of a Commercial Drug |
Vol. 7 No. 1 |
44 |
Calculations |
Vol. 7 No. 1 |
46 |
Featured Excipient: Flavor Enhancing Agents |
Vol. 7 No. 1 |
48 |
Basics of Compounding for Terrorist Attacks, Part 1 |
Vol. 7 No. 1 |
51 |
Amoxicillin 125-mg/5-mL and 250-mg/5-mL Suspensions |
Vol. 7 No. 1 |
55 |
Atropine 1-mg Gelatin Troches |
Vol. 7 No. 1 |
56 |
Atropine Sulfate 0.1% for Inhalation |
Vol. 7 No. 1 |
57 |
Atropine Sulfate 0.5-mg/mL Injection |
Vol. 7 No. 1 |
58 |
Gentamicin Sulfate 40-mg/mL Injection |
Vol. 7 No. 1 |
59 |
Levofloxacin 250-mg/5mL Oral Liquid |
Vol. 7 No. 1 |
60 |
Ofloxacin 250-mg/5-mL Oral Liquid |
Vol. 7 No. 1 |
60 |
Potassium Iodide 130-mg Capsules and Potassium Iodide 16-mg/mL Oral Liquid |
Vol. 7 No. 1 |
61 |
Ribavirin 200-mg Capsules |
Vol. 7 No. 1 |
62 |
Sodium Hypochlorite Disinfectant Solutions |
Vol. 7 No. 1 |
63 |
Vancomycin HCl 50-mg/mL Oral Solution |
Vol. 7 No. 1 |
64 |
Stability of Glycopyrrolate Injection at Ambient Temperature and 4°C in Polypropylene Syringes |
Vol. 7 No. 1 |
65 |
Stability of Succinylcholine Chloride Injection at Ambient Temperature and 4 Degree C in Polypropylene Syringes |
Vol. 7 No. 1 |
68 |
Use of Cysteine Hydrochloride Injection to Increase the Solubility of Calcium and Phosphates in FreAmine III-Containing Parenteral Nutrition Solutions |
Vol. 7 No. 1 |
71 |
Wish You Were Here: Deutsche Apotheken Museum (German Museum of Pharmacy) |
Vol. 7 No. 1 |
78 |
Postcription: Future Trends in High Technology Pharmaceutical Compounding |
Vol. 7 No. 1 |
80 |
Book and Literature Reviews |
Vol. 7 No. 2 |
84 |
Legal & Ethical Issues for Pharmacy Websites |
Vol. 7 No. 2 |
88 |
Panel Discussion: Prohormones |
Vol. 7 No. 2 |
94 |
Profile of a Practice: Building a Compounding Pharmacy Practice from the Ground Up: Prescription Compounding Solutions, Medford, Oregon |
Vol. 7 No. 2 |
101 |
Veterinary Transdermal Medications: A to Z |
Vol. 7 No. 2 |
106 |
Autoclaves for the Sterilization of Compounded Parenteral Products |
Vol. 7 No. 2 |
114 |
Barcode System and Computerized Balance Speed Compounding and Enhance Accuracy |
Vol. 7 No. 2 |
118 |
Technology Spotlight: Electronic Balances with Printer and Draft Shield |
Vol. 7 No. 2 |
120 |
Accuracy of Small-Volume Containers |
Vol. 7 No. 2 |
124 |
Autoclave Efficiency Validation |
Vol. 7 No. 2 |
126 |
Calculations |
Vol. 7 No. 2 |
128 |
Basics of Compounding for Terrorist Attacks, Part 2 |
Vol. 7 No. 2 |
129 |
Amoxicillin 250-mg Troches |
Vol. 7 No. 2 |
131 |
Amoxicillin 125-mg Suppositories |
Vol. 7 No. 2 |
131 |
Chloramphenicol 250-mg Capsules |
Vol. 7 No. 2 |
131 |
Chloramphenicol 150-mg/5-mL Suspension |
Vol. 7 No. 2 |
131 |
Cidofovir Suppositories |
Vol. 7 No. 2 |
131 |
Ciprofloxacin Oral Suspension |
Vol. 7 No. 2 |
131 |
Clindamycin HCl 150-mg Capsules |
Vol. 7 No. 2 |
132 |
Clindamycin Phosphate 150-mg Capsules |
Vol. 7 No. 2 |
132 |
Clindamycin 10-mg/mL Oral Suspension |
Vol. 7 No. 2 |
132 |
Doxycycline HCl 100-mg Capsules |
Vol. 7 No. 2 |
132 |
Erythromycin 200-mg Troches |
Vol. 7 No. 2 |
132 |
Erythromycin 250-mg Suppositories |
Vol. 7 No. 2 |
132 |
Penicillin G Potassium 20,000,000-units Injection |
Vol. 7 No. 2 |
132 |
Penicillin G Potassium 1,000,000-unit Injection |
Vol. 7 No. 2 |
132 |
Ribavirin 33-mg/mL Injection |
Vol. 7 No. 2 |
132 |
Rifampin 10-mg/mL Oral Suspension |
Vol. 7 No. 2 |
132 |
Rifampin 150-mg Capsules |
Vol. 7 No. 2 |
132 |
Rifampin 3-mg/mL Intravenous Infusion |
Vol. 7 No. 2 |
132 |
Streptomycin Sulfate 400-mg/mL Injection |
Vol. 7 No. 2 |
132 |
Tetracycline 125-mg/5-mL Syrup |
Vol. 7 No. 2 |
132 |
Tetracycline HCl 20-mg/mL Intravenous Injection |
Vol. 7 No. 2 |
132 |
Tetracycline HCl 250-mg Capsules |
Vol. 7 No. 2 |
132 |
Tetracycline HCl 250-mg Suppositories |
Vol. 7 No. 2 |
133 |
Vancomycin HCl 250-mg Capsules |
Vol. 7 No. 2 |
133 |
Albuterol Sulfate 0.5% Inhalation Solution |
Vol. 7 No. 2 |
133 |
Dimercaptosuccinic Acid 250-mg Capsules |
Vol. 7 No. 2 |
133 |
Sodium Thiosulfate-Sodium Nitrate Solution |
Vol. 7 No. 2 |
133 |
Potassium Iodide Saturated Solution |
Vol. 7 No. 2 |
133 |
Lorazepam 2-mg Gelatin Troches |
Vol. 7 No. 2 |
134 |
Lorazepam 2-mg Polyethlene Glycol Troches |
Vol. 7 No. 2 |
134 |
Oral Liquid Suspending Vehicle |
Vol. 7 No. 2 |
134 |
Diazepam 5-mg/mL Injection |
Vol. 7 No. 2 |
135 |
Dimercaprol 100-mg/mL Injection USP |
Vol. 7 No. 2 |
136 |
Dimercaptopropanesulfonate Sodium 50-mg/mL Injection |
Vol. 7 No. 2 |
137 |
Lorazepam 2-mg Sublingual Tablets |
Vol. 7 No. 2 |
138 |
Mafenide Acetate 85 mg/g Cream USP |
Vol. 7 No. 2 |
139 |
Pralidoxime Chloride 50-mg/mL Injection |
Vol. 7 No. 2 |
140 |
Silver Sulfadiazine 1% Cream |
Vol. 7 No. 2 |
141 |
Sodium Bicarbonate 8.4% Injection USP |
Vol. 7 No. 2 |
142 |
Sodium Nitrite 3% Injection USP |
Vol. 7 No. 2 |
143 |
Sodium Thiosulfate 25% Injection USP |
Vol. 7 No. 2 |
144 |
Featured Excipient: Plasticizers |
Vol. 7 No. 2 |
145 |
Stability of Clindamycin Phosphate in AutoDose Infusion System Bags |
Vol. 7 No. 2 |
149 |
Chemical Stability of Cefazolin Sodium after Reconstituting in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use |
Vol. 7 No. 2 |
152 |
Quantification of Total Dexamethasone Phosphate Delivery by Iontophoresis |
Vol. 7 No. 2 |
155 |
PostScription: Sterile Product Admixture Preparation |
Vol. 7 No. 2 |
160 |
Book & Literature Reviews |
Vol. 7 No. 3 |
164 |
Five Compounds for Treating Diabetes-Related Conditions |
Vol. 7 No. 3 |
170 |
Ketamine 10 %, Gabapentin 6%, and Nifedipine 2% in PLO |
Vol. 7 No. 3 |
171 |
Sildenafil 25-mg Troches |
Vol. 7 No. 3 |
171 |
Prostaglandin E1/Papaverine HCl/Phentolamine Mesylate Injection |
Vol. 7 No. 3 |
171 |
Misoprostol 0.0024% and Phenytoin 5% Diabetic Ulcer Cream |
Vol. 7 No. 3 |
171 |
Nifedipine 100- mg/mL in PLO |
Vol. 7 No. 3 |
171 |
Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer |
Vol. 7 No. 3 |
176 |
The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP |
Vol. 7 No. 3 |
180 |
ABHR in PLO (Lorazepam, Diphenhydramine HCl, Haloperidol, Metoclopramide HCl) |
Vol. 7 No. 3 |
183 |
Ketoprofen 10% in PLO |
Vol. 7 No. 3 |
183 |
Methimazole 5 mg/0.1 mL in PLO (Vet) |
Vol. 7 No. 3 |
183 |
Wish You Were Here: The Pearson Museum, Springfield, Illinois |
Vol. 7 No. 3 |
184 |
Treating Canine Hepatic Disease |
Vol. 7 No. 3 |
188 |
Incubators |
Vol. 7 No. 3 |
193 |
Further Clarification of HIPAA Regulations |
Vol. 7 No. 3 |
195 |
Software for the Compounding Pharmacist: An Update |
Vol. 7 No. 3 |
197 |
Technology Spotlight: Tube Sealers |
Vol. 7 No. 3 |
206 |
Accuracy of Graduated Cylinders |
Vol. 7 No. 3 |
208 |
Calculations |
Vol. 7 No. 3 |
212 |
Product Containment in the Compounding Laboratory |
Vol. 7 No. 3 |
213 |
Dexamethasone Phosphate 0.05% Ophthalmic Ointment |
Vol. 7 No. 3 |
215 |
Dexamethasone Phosphate 0.1% Topical Cream |
Vol. 7 No. 3 |
216 |
Dimenhydrinate 5-mg/mL Oral Liquid |
Vol. 7 No. 3 |
217 |
Epinephrine Bitartrate 2% Ophthalmic Solution |
Vol. 7 No. 3 |
218 |
Ergotamine Tartrate 2-mg Sublingual Tablets |
Vol. 7 No. 3 |
219 |
Hyoscyamine Sulfate 0.125-mg and Phenobarbital 15-mg/mL Oral Drops |
Vol. 7 No. 3 |
220 |
Methadone HCl 5-mg/mL Injection |
Vol. 7 No. 3 |
221 |
Minocycline 10-mg/mL Oral Liquid |
Vol. 7 No. 3 |
222 |
Phenytoin 6-mg/mL Oral Liquid |
Vol. 7 No. 3 |
223 |
Tetracycline HCl 2.2-mg/mL Topical Solution |
Vol. 7 No. 3 |
224 |
Quality-Control Analytical Methods: Principles of pH |
Vol. 7 No. 3 |
225 |
Standard Operating Procedure: Incubator Temperature Monitoring |
Vol. 7 No. 3 |
228 |
Stability of Amikacin Sulfate in AutoDose Infusion System Bags |
Vol. 7 No. 3 |
230 |
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets |
Vol. 7 No. 3 |
233 |
PostScription: Too Many Compounders? |
Vol. 7 No. 3 |
240 |
Book Reviews |
Vol. 7 No. 4 |
244 |
Literature Review |
Vol. 7 No. 4 |
246 |
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 |
Vol. 7 No. 4 |
250 |
Patient Satisfaction with Pharmacist Intervention and Consultation in HRT |
Vol. 7 No. 4 |
258 |
Sensitization Therapy for Warts |
Vol. 7 No. 4 |
266 |
Dinitrochlorobenzene 0.5% to 2.0% in Acetone |
Vol. 7 No. 4 |
270 |
Dinitrochlorobenzene 0.1% to 1 % in Hydrophilic Petrolatum |
Vol. 7 No. 4 |
270 |
Diphenylcyclopropenone 0.01% to 0.1% in Acetone |
Vol. 7 No. 4 |
270 |
Squaric Acid Dibutyl Ester 0.03% to 3.0 in Acetone |
Vol. 7 No. 4 |
270 |
Cantharidine 0.7% Topical |
Vol. 7 No. 4 |
270 |
Fluorouracil 5% Gel |
Vol. 7 No. 4 |
270 |
Podophyllum 25% in Compound Tincture of Benzoin |
Vol. 7 No. 4 |
270 |
Podophyllum 1% and Salicylic Acid 3% in Flexible Collodion |
Vol. 7 No. 4 |
270 |
Salicylic Acid 40% Ointment |
Vol. 7 No. 4 |
270 |
Effectiveness in Oral Rhus toxicodendron Solution for Poison Ivy Prevention |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 2X |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 3X |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 4X |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 5X |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 6X |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 7X |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 8X |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 9X |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 10X |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 11X |
Vol. 7 No. 4 |
272 |
Rhus Tox Solution 12X |
Vol. 7 No. 4 |
272 |
Rhus Tox 6X/12X Solution |
Vol. 7 No. 4 |
272 |
HIPAA Privacy and Security for Providers: The Basics |
Vol. 7 No. 4 |
277 |
Containment of Hazardous Particulates in the Compounding Pharmacy |
Vol. 7 No. 4 |
281 |
Technology Spotlight: A USP-Grade Water System |
Vol. 7 No. 4 |
286 |
Basics of Compounding for Raynaud's Disease |
Vol. 7 No. 4 |
288 |
Nifedipine in PLO Gel |
Vol. 7 No. 4 |
291 |
Nitroglycerin 0.2% Ointment |
Vol. 7 No. 4 |
291 |
Coenzyme Q10 100-mg-in-Oil Capsules |
Vol. 7 No. 4 |
291 |
Zinc, Magnesium, Caldium and Vitamin D3 Oral Liquid |
Vol. 7 No. 4 |
291 |
How to Handle a Product Recall |
Vol. 7 No. 4 |
292 |
Calculations |
Vol. 7 No. 4 |
294 |
Brompheniramine Maleate 2-mg/5-mL Oral Liquid |
Vol. 7 No. 4 |
295 |
Chlorpheniramine Maleate 10-mg/mL Injection |
Vol. 7 No. 4 |
296 |
Chlorpromazine HCl 30-mg/mL Oral Concentrate |
Vol. 7 No. 4 |
297 |
Desonide 0.05% Otic Liquid |
Vol. 7 No. 4 |
298 |
Hydroxyprogesterone Caproate 250-mg/mL-in-Oil Injection |
Vol. 7 No. 4 |
299 |
Meperidine HCl 100-mg/mL and Atropine Sulfate 0.4-mg/mL Injection |
Vol. 7 No. 4 |
300 |
Meperidine HCl 25-mg/mL and Promethazine HCl 25-mg/mL Injection |
Vol. 7 No. 4 |
301 |
Methocarbamol 400-mg and Aspirin 325-mg Capsules |
Vol. 7 No. 4 |
302 |
Perphenazine 4-mg and Amitriptyline HCl 10-mg capsules |
Vol. 7 No. 4 |
303 |
Triprolidine HCl 1.25-mg/5-mL, Pseudoephedrine HCl 30-mg/5-mL and Codeine Phosphate 10-mg/5-mL Oral Liquid |
Vol. 7 No. 4 |
304 |
Quality-Control Analytical Methods: Viscosity Measurements |
Vol. 7 No. 4 |
305 |
Chemical Stability of Cefuroxime Sodium After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use |
Vol. 7 No. 4 |
310 |
Stability of Hydralazine HCl in Both Flavored and Nonflavored Extemporaneous Preparations |
Vol. 7 No. 4 |
313 |
Postcription: Does Your Pharmacy Practice Follow the Pharmacist Code of Ethics? |
Vol. 7 No. 4 |
320 |
Book and Literature Reviews |
Vol. 7 No. 5 |
324 |
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 |
Vol. 7 No. 5 |
330 |
Patient Handout - Hormone Replacement Therapy |
Vol. 7 No. 5 |
339 |
The Role of the Pharmacist in Diabetes Care |
Vol. 7 No. 5 |
341 |
Understanding Feline Hyperthyroidism |
Vol. 7 No. 5 |
345 |
Profile of a Practice: Don West, RPh, Lloyd Center Pharmacy, Portland, Oregon |
Vol. 7 No. 5 |
350 |
Vancomycin Pluronic Gel |
Vol. 7 No. 5 |
354 |
Sterile Vancomycin Pluronic Gel for Implantation in the Chest-Wall Cavity to Treat Resistant Pneumococcus |
Vol. 7 No. 5 |
354 |
NDC Numbers: A New Approach |
Vol. 7 No. 5 |
358 |
Application of USP-NF Standards to Pharmacy Compounding |
Vol. 7 No. 5 |
361 |
Technology Spotlight: Respiratory Vial Sealers |
Vol. 7 No. 5 |
364 |
Basics of Compounding for Pediculosis |
Vol. 7 No. 5 |
366 |
Malathion 0.5% Topical Lotion |
Vol. 7 No. 5 |
368 |
Ivermectin 1% Crème Rinse |
Vol. 7 No. 5 |
368 |
Ivermectin 1% Lotion |
Vol. 7 No. 5 |
369 |
Head Lice Repellant Spray |
Vol. 7 No. 5 |
369 |
Standard Operating Procedure: Incubator Cleaning |
Vol. 7 No. 5 |
370 |
Calculations |
Vol. 7 No. 5 |
372 |
Chloramphenicol 1% Topical Ointment |
Vol. 7 No. 5 |
373 |
Guanethidine Monosulfate 10-mg and Hydrochlorothiazide 25-mg Capsules |
Vol. 7 No. 5 |
374 |
Indomethacin 50-mg Suppositories |
Vol. 7 No. 5 |
375 |
Isoniazid 10-mg/mL Oral Solution |
Vol. 7 No. 5 |
376 |
Pentazocine HCl 12.5-mg and Aspirin 325-mg Capsules |
Vol. 7 No. 5 |
377 |
Perphenazine 5-mg/mL Injection |
Vol. 7 No. 5 |
378 |
Phenylbutazone 100-mg Capsules |
Vol. 7 No. 5 |
379 |
Reserpine and Hydrochlorothiazide 0.125-mg/25-mg and 0.125-mg/50-mg Capsules |
Vol. 7 No. 5 |
380 |
Thioridazine HCl 100-mg/mL Concentrated Solution |
Vol. 7 No. 5 |
381 |
Ursodiol 150-mg Capsules |
Vol. 7 No. 5 |
382 |
Quality-Control Analytical Methods: Refractometry |
Vol. 7 No. 5 |
383 |
Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared with the Use of Powder |
Vol. 7 No. 5 |
386 |
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride |
Vol. 7 No. 5 |
389 |
Educating the Caregiver and Community Pharmacist To Facilitate Provision of Consistent Compounded Medications from the Inpatient to Ambulatory Settings |
Vol. 7 No. 5 |
394 |
Postcriptions: Compounding Paradox: Taught Less and Practiced More |
Vol. 7 No. 5 |
399 |
An Ounce of Prevention: Controlling Hazards in Extemporaneous Compounding Practices |
Vol. 7 No. 5 |
401 |
PreScription: Take Care with Terminology for Altered- and Slow-release Formulations |
Vol. 7 No. 6 |
418 |
Book & Literature Reviews |
Vol. 7 No. 6 |
420 |
Sore Nipples in Breastfeeding Mothers: Causes and Treatments |
Vol. 7 No. 6 |
426 |
Mupirocin 1%, Betamethasone 0.05%, and Miconazole 2% Nipple Ointment |
Vol. 7 No. 6 |
430 |
Mupirocin 0.5%, Betamethasone 0.025%, Nystatin 25,000-U/g and Clotrimazole 0.25% Nipple Ointment |
Vol. 7 No. 6 |
430 |
Mupirocin 0.5%, Betamethasone 0.025%, Nystatin 25,000-U/g and Clotrimazole 2.5% Nipple Ointment |
Vol. 7 No. 6 |
430 |
Compounding for Investigational Studies: The Experience of Ken Hughes, RPh |
Vol. 7 No. 6 |
436 |
Single-Patient Trials, Extemporaneously Compounded Products and Pharmaceutical Care |
Vol. 7 No. 6 |
441 |
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh |
Vol. 7 No. 6 |
449 |
A Foot in the Door: Marketing Tips |
Vol. 7 No. 6 |
454 |
Technology Spotlight: Automated Prescription-Dispensing Systems |
Vol. 7 No. 6 |
458 |
Basics of Compounding for Dry-Skin Conditions |
Vol. 7 No. 6 |
460 |
Wool Alcohols Ointment |
Vol. 7 No. 6 |
462 |
Water-Absorbing Ointment |
Vol. 7 No. 6 |
462 |
Natural Emollient Oil |
Vol. 7 No. 6 |
462 |
Emulsion Base to be Individualized |
Vol. 7 No. 6 |
462 |
Premixed Oil Phase for Preparing Oil-in-Water (O/W) Emulsions |
Vol. 7 No. 6 |
463 |
O/W Emulsion |
Vol. 7 No. 6 |
463 |
Lotion with Cyclomethicone |
Vol. 7 No. 6 |
463 |
Water-Repelling Lip-Balm Stick |
Vol. 7 No. 6 |
463 |
Lip-Balm Stick (Basic Formula for Individualizing) |
Vol. 7 No. 6 |
463 |
Water-Repelling Lip Ointment |
Vol. 7 No. 6 |
463 |
Lip Ointment (Basic Ointment for Individualizing) |
Vol. 7 No. 6 |
463 |
Storage of Bulk Chemicals and Finished Preparations |
Vol. 7 No. 6 |
464 |
Calculations |
Vol. 7 No. 6 |
466 |
Bacitracin 500-U/g Ophthalmic Ointment |
Vol. 7 No. 6 |
467 |
Chloramphenicol 0.5% Ophthalmic Solution |
Vol. 7 No. 6 |
468 |
Clotrimazole 500-mg Vaginal Suppositories |
Vol. 7 No. 6 |
469 |
Ergoloid Mesylate 1-mg/mL Oral Liquid |
Vol. 7 No. 6 |
470 |
Meclocycline Sulfosalicylate 1% Cream |
Vol. 7 No. 6 |
471 |
Methadone HCl 2.5-mg Capsules |
Vol. 7 No. 6 |
472 |
Perphenazine 2.5-mg/5-mL Syrup |
Vol. 7 No. 6 |
473 |
Sulfasalazine 250-mg/5-mL Oral Liquid |
Vol. 7 No. 6 |
474 |
Tramadol HCl 100-mg Capsules |
Vol. 7 No. 6 |
475 |
Triprolidine HCl 2.5-mg Capsules |
Vol. 7 No. 6 |
476 |
Quality-Control Analytical Methods: Specific-Gravity Determinations of Liquids and Semisolids |
Vol. 7 No. 6 |
477 |
Pharmacokinetics of Sumatriptan 25-mg Oral Tablet Versus 25-mg Extemporaneous Suppository in Healthy Volunteers |
Vol. 7 No. 6 |
481 |
Stability of Two Concentrations of Tiagabine in an Extemporaneously Compounded Suspension |
Vol. 7 No. 6 |
485 |
Patient Interest in Pharmacist-Provided Menopause and Hormone Replacement Therapy Consultations |
Vol. 7 No. 6 |
490 |
PostScription: Changing Pharmacy Regulations Could Affect US Compounders |
Vol. 7 No. 6 |
495 |